US Breast Cancer HCP Survey · n=300

Congress engagement

How HCPs consume congress content across the journey, and what MSL + digital orchestration should look like for each profile.

Overall - before · during · after

Before
  • Expert perspectives on key topics expected to be discussed41%i100
  • Refreshers on existing data or current treatment approaches38%i100
  • Summaries of existing data to help interpret new clinical and scientific data that will be presented at the congress38%i100
  • Study design overviews or key endpoints to watch32%i100
  • Summaries of key trials to watch out for31%i100
During
  • Expert panel discussions43%i100
  • Clinical practice or case-based sessions32%i100
  • Guideline update sessions31%i100
  • Oral abstract sessions presenting late‑breaking or pivotal data25%i100
  • Peer discussions24%i100
  • Poster sessions and focused ?poster discussions14%i100
  • Scientific symposia (industry-sponsored)11%i100
  • Scientific symposia (medical society-led/ satellite symposia)10%i100
After
  • Expert perspectives on key topics expected to be discussed41%i100
  • Refreshers on existing data or current treatment approaches38%i100
  • Summaries of existing data to help interpret new clinical and scientific data that will be presented at the congress38%i100
  • Study design overviews or key endpoints to watch32%i100
  • Summaries of key trials to watch out for31%i100

MSL × digital orchestration by profile

Each profile below shows its top pre / during / post congress preference plus the MSL situation it values most. Use this to plan paired digital + MSL pulses around each congress.

Academic · research-active
  1. 1
    Pre - digital priming
    Expert perspectives on key topics expected to be discussed (43%)
  2. 2
    During - congress focus
    Expert panel discussions (43%)
  3. 3
    During - MSL 1:1
    After reviewing relevant data independently, to clarify questions ?or uncertainties (36%)
  4. 4
    After - digital follow-up
    Expert perspectives on key topics expected to be discussed (43%)
Community · high-volume
  1. 1
    Pre - digital priming
    Expert perspectives on key topics expected to be discussed (53%)
  2. 2
    During - congress focus
    Expert panel discussions (60%)
  3. 3
    During - MSL 1:1
    After reviewing relevant data independently, to clarify questions ?or uncertainties (26%)
  4. 4
    After - digital follow-up
    Expert perspectives on key topics expected to be discussed (53%)
Early-career · academic
  1. 1
    Pre - digital priming
    Expert perspectives on key topics expected to be discussed (57%)
  2. 2
    During - congress focus
    Expert panel discussions (60%)
  3. 3
    During - MSL 1:1
    After reviewing relevant data independently, to clarify questions ?or uncertainties (40%)
  4. 4
    After - digital follow-up
    Expert perspectives on key topics expected to be discussed (57%)
Experienced · community · not research
  1. 1
    Pre - digital priming
    Refreshers on existing data or current treatment approaches (45%)
  2. 2
    During - congress focus
    Expert panel discussions (43%)
  3. 3
    During - MSL 1:1
    After reviewing relevant data independently, to clarify questions ?or uncertainties (27%)
  4. 4
    After - digital follow-up
    Refreshers on existing data or current treatment approaches (45%)

Pre-congress - Academic vs Community

Community
  • Summaries of existing data to help interpret new clinical and scientific data that will be presented at the congress42%i110
  • Refreshers on existing data or current treatment approaches42%i110
  • Expert perspectives on key topics expected to be discussed42%i101
  • Summaries of key trials to watch out for31%i102
  • Study design overviews or key endpoints to watch26%i80
Academic
  • Expert perspectives on key topics expected to be discussed41%i100
  • Study design overviews or key endpoints to watch39%i122
  • Refreshers on existing data or current treatment approaches34%i89
  • Summaries of existing data to help interpret new clinical and scientific data that will be presented at the congress34%i88
  • Summaries of key trials to watch out for29%i96

Post-congress - Academic vs Community

Community
  • Summaries of existing data to help interpret new clinical and scientific data that will be presented at the congress42%i110
  • Refreshers on existing data or current treatment approaches42%i110
  • Expert perspectives on key topics expected to be discussed42%i101
  • Summaries of key trials to watch out for31%i102
  • Study design overviews or key endpoints to watch26%i80
Academic
  • Expert perspectives on key topics expected to be discussed41%i100
  • Study design overviews or key endpoints to watch39%i122
  • Refreshers on existing data or current treatment approaches34%i89
  • Summaries of existing data to help interpret new clinical and scientific data that will be presented at the congress34%i88
  • Summaries of key trials to watch out for29%i96